Aliskiren/amlodipine
The drug combination aliskiren/amlodipine (INNs, trade names Tekamlo and Rasilamlo) is an antihypertensive. Clinical trials have shown it to be more effective than amlodipine on its own,[1] with a high dosing regime (aliskiren 300 mg/amlodipine 10 mg) being more effective than olmesartan/amlodipine with comparable tolerability.[2]
Combination of | |
---|---|
Aliskiren | Renin inhibitor |
Amlodipine | Calcium channel blocker (dihydropyridine) |
Clinical data | |
Trade names | Tekamlo, Rasilamlo |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
(what is this?) (verify) |
References
- Pfeiffer D, Rennie N, Papst CC, Zhang J (November 2012). "Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥". Current Vascular Pharmacology. 10 (6): 773–80. doi:10.2174/157016112803520945. PMID 22303911.
- Axthelm C, Sieder C, Meister F, Kaiser E (January 2012). "Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg". Current Medical Research and Opinion. 28 (1): 69–78. doi:10.1185/03007995.2011.637914. PMID 22117838. S2CID 25693979.
Further reading
External links
- "Aliskiren mixture with amlodipine". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.